ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC

ClinicalTrials.gov ID: NCT03822351

Public ClinicalTrials.gov record NCT03822351. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 10:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab (MEDI4736) Alone or in Combination With Novel Agents in Subjects With Locally Advanced, Unresectable (Stage III) Non-small Cell Lung Cancer (COAST)

Study identification

NCT ID
NCT03822351
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
MedImmune LLC
Industry
Enrollment
189 participants

Conditions and interventions

Interventions

  • Durvalumab Drug
  • Durvalumab + Monalizumab Drug
  • Durvalumab + Oleclumab Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 99 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 18, 2018
Primary completion
Jul 17, 2023
Completion
Jul 17, 2023
Last update posted
Oct 7, 2024

2018 – 2023

United States locations

U.S. sites
28
U.S. states
18
U.S. cities
27
Facility City State ZIP Site status
Research Site Anaheim California 92801
Research Site Duarte California 91010
Research Site Sacramento California 95825
Research Site New Haven Connecticut 06510
Research Site West Haven Connecticut 06516
Research Site Washington D.C. District of Columbia 20007
Research Site Orlando Florida 32804
Research Site Winter Haven Florida 33881
Research Site Wichita Kansas 67214
Research Site Lexington Kentucky 40503
Research Site Louisville Kentucky 40202
Research Site Baton Rouge Louisiana 70809
Research Site Covington Louisiana 70433
Research Site Rosedale Maryland 21237
Research Site Lincoln Nebraska 68510
Research Site New York New York 10029
Research Site New York New York 10065
Research Site Portland Oregon 97227-1191
Research Site Gettysburg Pennsylvania 17325
Research Site Lancaster Pennsylvania 17601
Research Site Philadelphia Pennsylvania 19104
Research Site Sioux Falls South Dakota 57105
Research Site Germantown Tennessee 38138
Research Site Memphis Tennessee 38120
Research Site Tyler Texas 75701
Research Site Salt Lake City Utah 84112
Research Site Richmond Virginia 23230
Research Site Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 45 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03822351, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 7, 2024 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03822351 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →